

#### (19) World Intellectual Property Organization International Bureau



# 

(43) International Publication Date 4 March 2004 (04.03.2004)

**PCT** 

(10) International Publication Number WO 2004/018710 A3

(51) International Patent Classification7:

C12Q 1/68

79104 Freiburg (DE). SCHERER, Andreas [DE/DE]; Kirchstrasse 11, 79618 Rheinfelden-Herten (DE).

(21) International Application Number:

PCT/EP2003/009292

tual Property, CH-4002 Basel (CH).

(22) International Filing Date: 21 August 2003 (21.08.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/405,225

22 August 2002 (22.08.2002) US

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMHBH [AT/AT]; Brunner Stasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KRAUSE, Andreas [DE/CH]; Feldstrasse 103, CH-4123 Allschwill (CH). NIESE, Detlef [DE/DE]; Mercystrasse 15, 79100 Freiburg (DE). RAULF, Friedrich [DE/DE]; Merianstrasse 29,

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,

LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellec-

(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

#### Published:

with international search report

(88) Date of publication of the international search report: 23 September 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

\_\_\_\_\_

(54) Title: DIAGNOSIS OF CHRONIC REJECTION

(57) Abstract: Methods are disclosed for, early diagnosing chronic rejection (CR) in a transplanted subject, monitoring CR in a transplanted subject at risk of developing CR, preventing, inhibiting, reducing or treating CR in a transplanted subject, or identifying agents for use in the prevention, inhibition, reduction or treatment of CR, based on genes which are differentially expressed in transplant biopsy tissues, before any overt clinical or histological manifestation of CR is detected in the transplanted subject.

# BEST AVAILABLE COPY INTERNATIONAL SEARCH REPORT

Intern	Application No
PCT	03/09292

		101	5703E3E	
IPC 7	FICATION OF SUBJECT MANAGE C12Q1/68			
According to International Patent Classification (IPC) or to both national classification and IPC				
	SEARCHED			
Minimum documentation searched (classification system followed by classification symbols)  IPC 7 C12Q				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic d	ata base consulted during the international search (name of data ba	se and, where practical, search terms use	d)	
EPO-Internal, BIOSIS, MEDLINE, WPI Data, PAJ				
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the rel	evant passages	Relevant to claim No.	
х	SUTHANTHIRAN M: "Human renal al rejection: molecular characteriz NEPHROLOGY, DIALYSIS, TRANSPLANT OFFICIAL PUBLICATION OF THE EURO DIALYSIS AND TRANSPLANT ASSOCIAT EUROPEAN RENAL ASSOCIATION. ENGL vol. 13 Suppl 1, 1998, pages 21-XP002267088	ation." ATION: PEAN ION - AND 1998,	1,5,6, 10,11	
Υ	ISSN: 0931-0509 the whole document 	-/	2-4,7-9, 12-14	
[V] Engl	or documents are listed in the continuation of hour			
	Further documents are listed in the continuation of box C. Patent family members are listed in annex.		in annex.	
<ul> <li>Special categories of cited documents:</li> <li>"A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>"E" earlier document but published on or after the international filing date</li> <li>"E" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>"O" document referring to an oral disclosure, use, exhibition or</li> </ul>		the application but the control of the control of the considered to the considered to the control of the contro		
other n "P" docume	other means other means  P' document published prior to the international filing date but later than the priority date claimed  and other means ments, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family		ous to a person skilled	
Date of the a	actual completion of the international search	Date of mailing of the international sea		
1	6 January 2004		2 7 05. 2004	
Name and m	nailing address of the ISA European Parent Office, P.B. 5818 Patentlaan 2	Authorized officer		
NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Botz, J		

Intern Application No INTERNATIONAL SEARCH REPORT PCT 03/09292 C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Χ "Molecular correlates SHARMA V K ET AL: 1,5,6, of human renal allograft rejection" 10,11 TRANSPLANTATION PROCEEDINGS, vol. 30, no. 5, August 1998 (1998-08), pages 2364-2366, XP002267089 Meeting on New Dimensions in Transplantation: Weaving the Future; Florence, Italy; February 16-19, ISSN: 0041-1345 Y the whole document 2-4,7-9, 12-14 X TANG W H ET AL: "Activation of the serine 1,5,6, proteinase system in chronic kidney
rejection." 10,11 TRANSPLANTATION. UNITED STATES 27 JUN 1998, vol. 65, no. 12, 27 June 1998 (1998-06-27), pages 1628-1634, XP008026499 ISSN: 0041-1337 the whole document Υ 2-4,7-9, 12-14 X STREHLAU JURGEN ET AL: "Quantitative 1,5,6, detection of immune activation transcripts 10,11 as a diagnostic tool in kidney transplantation" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES. vol. 94, no. 2, 1997, pages 695-700, XP002267122 1997 ISSN: 0027-8424 Υ the whole document 2-4,7-9, 12-14 Χ SUTHANTHIRAN MANIKKAM: "Clinical 1.5.6. application of molecular biology: A study 10,11 of allograft rejection with polymerase chain reaction" AMERICAN JOURNAL OF THE MEDICAL SCIENCES, vol. 313, no. 5, 1997, pages 264-267, XP008026444 ISSN: 0002-9629 Y page 264 - page 266; table 1 2-4,7-9, 12-14 -/--


Form PCT/ISA/210 (continuation of second sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

Inter Application No
PCT/ 03/09292

		13/09292		
C.(Continuation) DOCUMENTS CONSIDERATE TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Υ	DELARUE FRANCOISE ET AL: "Prognostic value of plasminogen activator inhibitor type 1 mRNA in microdissected glomeruli from transplanted kidneys" TRANSPLANTATION (BALTIMORE), vol. 72, no. 7, 15 October 2001 (2001-10-15), pages 1256-1261, XP008026393 ISSN: 0041-1337 the whole document	1-14		
Y	KAMOUN MALEK: "Cellular and molecular parameters in human renal allograft rejection" CLINICAL BIOCHEMISTRY, vol. 34, no. 1, February 2001 (2001-02), pages 29-34, XP001176799 ISSN: 0009-9120 page 30 - page 31	1-14		





Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
з. 🔲	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
з	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. X	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  1-14 (partially)
Remark	The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210
Continuation of Box I.1
Although claims 1-4 are directed to a diagnostic methods / methods of treatment involving a surgical / sample taking step (biopsy) from the living human/animal body, practised on the human/animal body, the search has been carried out and based on the prognostic indication of CR in relationship to the candidate genes mentioned.

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-14 (partially)

Invention number 1: A method of early diagnosing chronic rejection (CR) in a transplanted subject, a method for monitoring CR in a transplanted subject at risk of developing CR, a method of preventing, inhibiting, reducing or treating CR in a transplanted subject in need of such treatment, a method for identifying agents for use in the prevention, inhibition, reduction or treatment of CR, all said methods above taking into consideration the mRNA expression of the first gene of table 1, namely the gene cytokeratin 15 / KRT15 with the GenBank accession number X07696 (c.f. page 19 of the description of the underlying application), the use of a gene or an expression product of a gene, namely the gene cytokeratin 15 / KRT15 with the GenBank accession number X07696 as an early biomarker for transplant rejection, and, finally, the use of a compound which modulates the synthesis, expression of activity of one or more genes as identified in Table 1, 2 or 3, in particular of the gene cytokeratin 15 / KRT15, or an expression product thereof, for the preparation of a medicament for prevention or treatment of CR in a transplanted subject:

2. claims: 1-14 (partially)

Inventions 2 - 33: Idem for inventions 2 - 33, taking into consideration the mRNA expression levels of the genes mentioned in table 1 (from top to bottom);

3. claims: 1-14 (partially)

Inventions 34 - 65: Idem for inventions 34 - 65, taking into consideration the mRNA expression levels of the genes mentioned in table 2

(from top to bottom);